title: A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer.
abstract: OBJECTIVE
  This study was conducted to determine the clinical significance of serum M30 and M65 in epithelial ovarian cancer (EOC).
  
  
  METHODS
  A total of 56 patients with EOC and 56 healthy women were included in the study. All of the patients received platinum-based chemotherapy. Pretreatment levels of M30 and M65 were measured using the quantitative ELISA method.
  
  
  RESULTS
  The median M30 and M65 serum levels were significantly elevated in the EOC patients compared with the healthy controls (96.7 vs. 69.5, p = 0.028 and 436.4 versus 166.3, p < 0.001, respectively). The cut-off value of 423.4 U/L for M65 determined with ROC analysis, predicted progression with 75.1 % sensitivity and 65.6 % specificity (AUC = 0.708, p = 0.008). Patients with higher M65 levels had shorter progression-free survival (PFS) (p = 0.021). Both M30 and M65 serum levels were significantly higher for serous-type histology (p = 0.001 and p < 0.001, respectively). Increased M65 serum levels were associated with advanced disease (p = 0.005) and higher grade (p = 0.005). Moreover, M65 levels were higher for chemotherapy-resistant patients (p = 0.04). Multivariate analysis revealed that an elevated serum M65 level was the only significant independent prognostic factor (p = 0.039, HR 3.792).
  
  
  CONCLUSIONS
  These results indicated that serum M30 and M65 levels were significantly elevated in patients with EOC compared with healthy women. Particularly, high serum M65 levels were associated with poor prognosis and resistance to platinum-based chemotherapy.
authors.affiliation: Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey. dr_ibrahim2000@yahoo.com
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Yildiz
authors.forename: Faruk
authors.initials: F
authors.lastname: Tas
authors.forename: Leyla
authors.initials: L
authors.lastname: Kilic
authors.forename: Fatma
authors.initials: F
authors.lastname: Sen
authors.forename: Pinar
authors.initials: P
authors.lastname: Saip
authors.forename: Yesim
authors.initials: Y
authors.lastname: Eralp
authors.forename: Serkan
authors.initials: S
authors.lastname: Keskin
authors.forename: Senem
authors.initials: S
authors.lastname: Karabulut
authors.forename: Rumeysa
authors.initials: R
authors.lastname: Ciftci
authors.forename: Murat
authors.initials: M
authors.lastname: Serilmez
authors.forename: Vildan
authors.initials: V
authors.lastname: Yasasever
authors.forename: Adnan
authors.initials: A
authors.lastname: Aydiner
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000097:blood*; D000077216:Carcinoma, Ovarian Epithelial; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D053538:Keratin-18 / Q000097:blood*; D008875:Middle Aged; D015999:Multivariate Analysis; D009375:Neoplasms, Glandular and Epithelial / Q000097:blood* / Q000401:mortality / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology*; D010446:Peptide Fragments / Q000097:blood*; D011379:Prognosis; D012372:ROC Curve; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D006454:Hemoglobins; D053538:Keratin-18; C561463:M30 cytokeratin-18 peptide, human; C577325:M65 antigen, human; D010446:Peptide Fragments